Clinical Trials Logo

Cancer of Pancreas clinical trials

View clinical trials related to Cancer of Pancreas.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04128332 Active, not recruiting - Cancer of Pancreas Clinical Trials

Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer

PORTICO-SABR
Start date: October 26, 2020
Phase: N/A
Study type: Interventional

A window of opportunity feasibility study assessing pre-operative stereotactic ablative body radiotherapy followed by immediate surgery in pancreatic adenocarcinoma.

NCT ID: NCT03347162 Active, not recruiting - Cancer Clinical Trials

Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer

Start date: December 1, 2017
Phase:
Study type: Observational

PURPOSE: To determine the prognostic properties of a comprehensive evaluation of body composition and physical function in patients with GI-HEP cancer from point of diagnosis and throughout the treatment trajectory. GI-HEP: Patients with tumors of the upper gastrointestinal or hepatobiliary tract, specifically tumors of the esophagus, gastro-esophageal junction, stomach, primary tumors of the liver or biliary tract, as well as colorectal liver metastasis or tumors of the pancreas.

NCT ID: NCT02905578 Active, not recruiting - Pancreas Cancer Clinical Trials

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

Start date: November 28, 2018
Phase: Phase 2
Study type: Interventional

This clinical trial adds high-dose ascorbate (vitamin C) to the standard of care regimen for metastatic pancreatic adenocarcinoma (a type of pancreatic cancer). Subjects are randomized between a control group (standard treatment) and an intervention group (pharmacologic ascorbate in addition to the standard treatment).

NCT ID: NCT02902484 Active, not recruiting - Cancer of Pancreas Clinical Trials

Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer

Start date: September 7, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The study will perform a clinical study evaluating the safety and tolerability of nintedanib when combined with standard chemotherapy (Gemcitabine + nab-Paclitaxel) for metastatic pancreatic cancer. It will utilize advanced imaging correlates including dynamic contrast enhanced Magnetic Resonance Imaging (DCE-MRI) which correlates with tumor grade and microvessel density.